Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Nicox S.A. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. The company's lead product candidate, NCX 470, is designed to treat glaucoma and ocular hypertension, leveraging its proprietary nitric oxide-donating technology to enhance intraocular pressure reduction. Nicox operates primarily in Europe and the U.S., positioning itself in a competitive market with significant unmet medical needs.
Nicox generates revenue through the development and potential commercialization of its ophthalmic products, particularly NCX 470. The company benefits from a unique competitive advantage through its proprietary technology that enhances the efficacy of existing treatments, allowing for premium pricing. Partnerships with larger pharmaceutical companies could also provide milestone payments and royalties.
Clinical trial results for NCX 470, particularly Phase 3 outcomes
Regulatory approvals from the FDA or EMA
Partnership announcements with larger pharmaceutical companies
Market adoption rates post-launch
Regulatory changes impacting drug approval processes
Technological disruption in ophthalmic treatments
Emergence of alternative therapies for glaucoma
Increased competition from established pharmaceutical companies
Limited cash reserves impacting operational flexibility
Potential dilution from future capital raises
low - The demand for ophthalmic treatments is relatively inelastic, less affected by economic cycles.
Minimal impact as Nicox is not heavily reliant on debt financing, but higher rates could affect overall market sentiment towards biotech investments.
minimal
growth - Investors are likely attracted to the potential for rapid revenue growth upon successful product commercialization.
high - The stock is likely to exhibit high volatility due to binary outcomes associated with clinical trials and regulatory approvals.